11.05% CAGR for Atrial Fibrillation Market to 2019 - A Global Forecast

DALLAS, January 31, 2015 /PRNewswire/ --

LifeScienceIndustryResearch.com offers Global Atrial Fibrillation Market 2015-2019 research report of 67 pages that profiles atrial fibrillation industry players like Boehringer Ingelheim GmbH, Janssen Pharmaceuticals Inc. and Sanofi SA.

The growing focus on emerging markets by drug manufacturers is one key trend witnessed in the Atrial Fibrillation market. Vendors are increasingly focusing on emerging markets owing to the lower production costs and the presence of lenient regulatory guidelines. Lenient regulatory guidelines, low manufacturing costs, skilled labor, and limited competition in the market are some of the factors that result in a decrease in the developmental costs of medical devices and an increase in the profit margins of manufacturers.

Analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05% over the period 2014-2019.

According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest types of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

Based on the "Global Atrial Fibrillation Market 2015-2019" report analysis, an increase in the patient population is one of the major factors propelling the growth of the market. The high prevalence of atrial fibrillation in patients worldwide, especially among people aged 60 and above, leads to an increase in the treatment-seeking patient population and increased consumption of medicines.

Order a copy of this report at (Prices start at US $2500 for a Single user PDF) http://www.lifescienceindustryresearch.com/purchase?rname=33348.

This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

The report recognizes the following companies as the key players in the Global Atrial Fibrillation Market: Boehringer Ingelheim GmbH, Janssen Pharmaceuticals Inc. and Sanofi SA.

Other Prominent Vendors in the market are: ARCA Biopharma, Armetheon, Baxter, Bristol-Myers Squibb, ChanRx, Daiichi Sankyo, Gilead Sciences, HUYA Biosciences, Menarini, Pfizer, Pierre Fabre, Servier and Xention.

Key Questions Answered in this Report: What will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?

List of Exhibits: 

Exhibit 1: Market Research Methodology
Exhibit 2: Types of Atrial Fibrillation
Exhibit 3: Risk Factors Associated with Atrial Fibrillation
Exhibit 4: Management of Atrial Fibrillation
Exhibit 5: Economic Burden of Atrial Fibrillation
Exhibit 6: Global Atrial Fibrillation Market 2014-2019 (US$ million)
Exhibit 7: Challenges and Drivers of Global Atrial Fibrillation Market
Exhibit 8: Global Atrial Fibrillation Market Segmentation by Class of Drugs
Exhibit 9: Sub-classification of Anti-arrythmics
Exhibit 10: Segmentation of Global Atrial Fibrillation Market by Geography 2014
Exhibit 11: Buying Criteria of the Global Atrial Fibrillation market
Exhibit 12: World's Population Aged 60 and Above (2010-2020)
Exhibit 13: The Global Prevalence of Atrial Fibrillation 2006-2016 (Million)
Exhibit 14: Drivers and their Impact on the Key Customer Category of the Global Atrial Fibrillation market
Exhibit 15: Drivers and their Impact on Geographies in Global Atrial Fibrillation Market
Exhibit 16: Global Atrial Fibrillation Market Share Analysis 2014
Exhibit 17: Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 18: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 20: Sanofi SA: Business Segmentation
Exhibit 21: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 22: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 23: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

Explore Other New Reports on Pharmaceuticals Market.

About Us      

Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441

[email protected]

SOURCE Life Science Industry Research